Sanofi (NASDAQ: SNY): Q3 2019 Earnings Snapshot

— Generic drugmaker Sanofi (NASDAQ: SNY) reported net income of EUR 1.77 billion or EUR 1.49 per share for the third quarter, on IFRS basis, down 23.% and 18.6% respectively from last year — IFRS net sales increased 1.1% year-over-year to EUR 9.5 billion, on a reported basis — Sanofi Genzyme sales rose 19.5% annually, […]

$SNY October 31, 2019 1 min read

NYSE

$SNY · Earnings

“
— Generic drugmaker Sanofi (NASDAQ: SNY) reported net income of EUR 1.77 billion or EUR 1.49 per share for the third quarter, on IFRS basis, down 23.% and 18.6% respectively from last year — IFRS net sales increased 1.1% year-over-year to EUR 9.5 billion, on a reported basis — Sanofi Genzyme sales rose 19.5% annually, […]
· October 31, 2019

— Generic drugmaker Sanofi (NASDAQ: SNY) reported net income of EUR 1.77 billion or EUR 1.49 per share for the third quarter, on IFRS basis, down 23.% and 18.6% respectively from last year

— IFRS net sales increased 1.1% year-over-year to EUR 9.5 billion, on a reported basis

— Sanofi Genzyme sales rose 19.5% annually, aided by continued strong uptake of Dupixent

— Vaccine sales decreased 9.8%, reflecting anticipated weighing of flu vaccine supply towards year-end

— Expects business earnings to grow about 5%, on a constant-currency basis and excluding one-off items, in fiscal 2019

— During the quarter, European Commission approved Dupixent for severe chronic rhinosinusitis

— Achieved positive results from advanced-stage study on Dupixent for severe atopic dermatitis in children

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Related Articles

Alight Faces $3.1B Goodwill Hit, Bets on AI and Operational Overhaul for 2026

Orion Engineered Carbons Confronts Cycle Lows With Cost Reset and Disciplined 2026 Outlook

Avient Powers Through 2025 on Non-PFAS Innovation and SEM Momentum, Sets Sights on 2026 Growth